| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Biowatch Alert: Vion Jumps On Strong Volume, No News
Posted on 05/23/2007 07:43:15 | Link | Post Comment
by H.S. Ayoub
BioHealthInvestor.com
Shares of Vion Pharmaceuticals (VION) gained more than 6% on Tuesday as volume was almost five times the 3 month daily average!
There were no news or any significant events that could be detected.
Vion develops and commercializes products for the treatment of cancer, including Cloretazine, an alkylating agent that is undergoing a Phase 3 trial for the treatment of relapsed acute myelogenous leukemia (AML), and a Phase 2 trial for the treatment of de novo poor-risk AML in previously untreated elderly patients; and Triapine, a small molecule for the prevention of the replication of tumor cells.
The company has a tiny market cap of only $147 million. It has almost $80 million in cash and more than $50 million in debt according to the latest Yahoo! financial data.
Shares of Vion closed at $2.02 on Tuesday, 12% below the 52-week high of $2.30.
Vion has made BHI's BioWatch Alert List, and will be tracked for the next two weeks.
Source: BioHealthInvestor.com
_____________________
BioHealthInvestor.com
Shares of Vion Pharmaceuticals (VION) gained more than 6% on Tuesday as volume was almost five times the 3 month daily average!
There were no news or any significant events that could be detected.
Vion develops and commercializes products for the treatment of cancer, including Cloretazine, an alkylating agent that is undergoing a Phase 3 trial for the treatment of relapsed acute myelogenous leukemia (AML), and a Phase 2 trial for the treatment of de novo poor-risk AML in previously untreated elderly patients; and Triapine, a small molecule for the prevention of the replication of tumor cells.
The company has a tiny market cap of only $147 million. It has almost $80 million in cash and more than $50 million in debt according to the latest Yahoo! financial data.
Shares of Vion closed at $2.02 on Tuesday, 12% below the 52-week high of $2.30.
Vion has made BHI's BioWatch Alert List, and will be tracked for the next two weeks.
Source: BioHealthInvestor.com
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Trader X
- Real Estate Marketing Blog
- Morpheus Trading
- Alpha Trends
- Millionaire Now! by Larry Nusbaum
- Random Roger's Big Picture
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home